The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
Jasjeet Bhullar(University of Maryland, Baltimore), Maria R. Baer(University of Maryland, Baltimore), Trevor J. Mathias(University of Maryland, Baltimore), Karthika Natarajan(Center for Drug Evaluation and Research), Mariola Sadowska(University of Maryland, Baltimore), Suneet Shukla(National Cancer Institute), Suresh V. Ambudkar(National Institutes of Health)
Cited by 32
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764